Has Charles van Meter, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,918 in general payments to Charles van Meter, MD across 166 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Charles van Meter, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Charles van Meter, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Charles van Meter, MD

Psychiatry · Troy, NYNPI 1699963884

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 30.6% of the total. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,918in general payments, 2019–2025

Across 166 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Otsuka America Pharmaceutical, Inc.$727
Johnson & Johnson$626
Alkermes, Inc.$353
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$214
Teva Pharmaceuticals USA, Inc.$181
plus $616 from 10 others

What the payments were for

Food & beverage$3,918100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	58	$1,201
Otsuka America Pharmaceutical, Inc.	24	$727
Johnson & Johnson(2 entities)	26	$626
Alkermes, Inc.	10	$353
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	13	$214
Teva Pharmaceuticals USA, Inc.	4	$181
Neurocrine Biosciences, Inc.	7	$128
Takeda Pharmaceuticals U.S.A., Inc.	7	$117
Axsome Therapeutics, Inc.	4	$87
Vanda Pharmaceuticals Inc.	5	$84
Corium, LLC	2	$67
Collegium Pharmaceutical, Inc.	2	$47
Harmony Biosciences LLC	1	$30
Supernus Pharmaceuticals, Inc.	1	$21
Lundbeck LLC	1	$21
Merck	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,918 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Medicare billing

Part B allowed, 2024

$172,868

Medicare patients

Services billed

822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Atomoxetine Hcl	19	$1,062
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	13	$759
Bupropion XlBupropion Hcl	29	$709
Ropinirole Hcl	12	$570
Mirtazapine	26	$349
Divalproex Sodium ErDivalproex Sodium	29	$321
Aripiprazole	14	$316
Sertraline Hcl	21	$248
Buspirone Hcl	34	$203
Lamotrigine	14	$164
Venlafaxine Hcl ErVenlafaxine Hcl	16	$113
Fluoxetine Hcl	13	$84
Propranolol Hcl	12	$64
Duloxetine Hcl	11	$59
Trazodone Hcl	12	$34

Paid to pharmacies, not to this prescriber.

Other psychiatry in Troy

Leslie CitromePomona$5.7M
Sanjay GuptaCheektowaga$1.9M
Richard PriceMonsey$1.7M
Adam AshtonAmherst$1.6M
Christoph CorrellGlen Oaks$1.5M
Manish ZinzuvadiaNew York$1.3M
George KruseBronx$1.2M
Jianping ChenNew York$1.2M
Horacio CapoteAmherst$1.1M
Yadagiri ChepuruYonkers$963K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →